T3 Pharma is a biotechnology company focused on developing targeted cancer therapies utilizing its proprietary T Cell Receptor (TCR) platform.

T3 Pharmaceuticals AG

T3 Pharma

Developing the next generation bacterial cancer therapyThe vision of T3 Pharmaceuticals is to improve the lives of cancer patients with highly innovative treatments. Despite significant advances of classical therapies, there remains a high need for novel and innovative medicines to treat cancer. T3 Pharmaceuticals is dedicated to fill this gap by developing highly specific and efficient treatments using live bacteria.T3 Pharmaceuticals was founded in May 2015 by Simon Ittig, Christoph Kasper, Marlise Amstutz and Helmut Kessmann as a spin-off of the University of Basel. The team has developed an efficient protein delivery technology that is based on the use of live bacteria. While the technology has diverse applications in research, T3 Pharma has further developed the system to serve as a novel therapeutic to treat solid tumors.

COM:T3PHARMA

T3 Pharma

name

homepage url

country

linkedin url

crunchbase url

employee count

sector

industry

Description

peer of

Metrics